OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChinese University of Hong Kong

About this trial

In the management of patients with acute upper non-variceal upper gastrointestinal bleeding, further bleeding is the most important adverse factor predictive of mortality. In the United Kingdom Audit on acute upper gastrointestinal bleeding, clinical evidence of further bleeding was reported in 13% of patients following the first endoscopy and 27% of them died. The use of OTSC has emerged as an alternative before angiographic embolization(TAE) which is often considered most definitive.

We propose to define the algorithm in the management of patients with refractory bleeding from their peptic ulcers or other non variceal causes. We hypothesize that endoscopic use of OTSC compares favourably with TAE and both lead to similar outcomes. An equivalence of the two modalities may mean that endoscopic application of OTSC should be attempted before TAE as often we need to document further bleeds with endoscopy and a second treatment should be instituted at the same time.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Patients presented with overt signs of acute upper gastrointestinal bleeding (hematemesis, melena and/or hypotension) 2. documented bleeding lesion at endoscopy (ulcer, dieulafoy's lesion and others), further bleeds (persistent or recurrent) after endoscopic hemostasis (thermal or hemoclips) as defined by an International Consensus Group

Disqualifiers

without a full informed consent from the patient or his next of kin

Age <18 years

Pregnant

Lactating women

Trial design

Design model

Parallel

Treatments tested in this trial

  • The OTSC® System Set

    Device

    The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion

  • angiographic embolization

    Procedure/Surgery

    Transcatheter selective embolization to bleeding arteries

Treatment groups

236 Participants
are divided into 2 treatment groups
Group A: Over-the-scope clipsExperimental treatment 1 intervention
Group B: angiographic embolizationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

further bleeding

Further bleeding is a composite of persistent or recurrent bleeding. Persistent bleeding is defined by active bleeding that cannot be stopped despite study intervention. For assessment of treatment efficacy, a repeat endoscopy can be performed to document further bleeding (fresh blood in the stomach and active bleeding or major stigmata of bleeding to the previously treated lesion).

Time frame
within 30 days after randomization

Secondary outcomes

1

further interventions

repeat endoscopic therapy, interventional radiology or surgery performed for management of further bleeds or a complication of a study intervention

Time frame
within 30 days after randomization
2

blood transfusion

total units of blood transfusion

Time frame
within 30 days after randomization
3

length of hospitalization

duration of hospitalization

Time frame
within 30 days after randomization
4

length of ICU stay

duration of ICU stay

Time frame
within 30 days after randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.